TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23078581

Group type: EXPERIMENTAL
Intervention: FT antireflux UIA (Group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Refluxing direct elliptical UIA (Group B)
Number of subjects: 49
Study: 21291437

Group type: EXPERIMENTAL
Intervention: Child FIRST
Number of subjects: 157

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 157
Study: 19400851

Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg)
Number of subjects: 49
Study: 16455787

Group type: EXPERIMENTAL
Intervention: Intrarectal sphere or latex balloon at 8, 6, or 4 cm from the anal verge
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control patients (asymptomatic women)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental patients (women with symptoms of difficult defecation)
Number of subjects: 24
Study: 15242465

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: SSRIs (overall)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 573
Study: 11431764

Group type: EXPERIMENTAL
Intervention: Pyloric traumamyoplasty (n = 43)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fredet-Ramstedt pyloromyotomy (n = 57)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pyloric traumamyoplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fredet-Ramstedt pyloromyotomy
Number of subjects: 100
Study: 10556611

Group type: EXPERIMENTAL
Intervention: Speech sounds (Finnish vowel /a/ with two different glottal excitations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tone sounds (sinusoidal stimulus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vowels with varying perceptual quality (from 'soft' /a/ to 'pressed' /A')
Number of subjects: 0
Study: 7644653

Group type: EXPERIMENTAL
Intervention: Automatic patient-instruction (API) device
Number of subjects: 128

Group type: COMPARATOR
Intervention: Technologist-performed patient instruction
Number of subjects: 128
Study: 2665559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.32 g alcohol/kg body weight
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.65 g alcohol/kg body weight
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.81 g alcohol/kg body weight
Number of subjects: 31
Study: 779949

Group type: COMPARATOR
Intervention: 5-FU 400 mg/m2 weekly intravenously
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: 5-FU 400 mg/m2 i.v. weekly plus methyl-CCNU 175 mg/m2 orally every 6 weeks
Number of subjects: 294
Study: 31125079

Group type: EXPERIMENTAL
Intervention: menthol Tobacco Heating System 2.2 (mTHS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: menthol cigarette
Number of subjects: 160

Group type: COMPARATOR
Intervention: smoking abstinence
Number of subjects: 160
Study: 30402705

Group type: EXPERIMENTAL
Intervention: Reduced bowel preparation (r‐CTC)
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Full bowel preparation (f‐CTC)
Number of subjects: 1286
Study: 29141858

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily subcutaneous injections for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily subcutaneous injections for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anakinra 12-week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anakinra 2-week
Number of subjects: 60
Study: 25579196

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture and ginger moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tropisetron hydrochloride and dexamethasone
Number of subjects: 60
Study: 23940237

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 5 ppm for 7 to 21 days
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study: 19926748

Group type: EXPERIMENTAL
Intervention: Bronchoreversibility
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Large changes in FVC
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Change in FEV(1)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: FVC improvements
Number of subjects: 544
Study: 18041047

Group type: EXPERIMENTAL
Intervention: Drug therapies for schizophrenic patients
Number of subjects: 0
Study: 16888462

Group type: COMPARATOR
Intervention: 6% carbohydrate drink (CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2% protein added to a 6% carbohydrate drink (CHO‐PRO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nonenergetic sweetened placebo (PLAC)
Number of subjects: 10
Study: 14636807

Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 41
Study: 11091928

Group type: EXPERIMENTAL
Intervention: Heart-rate feedback
Number of subjects: 54

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 54
Study: 2263306

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis with chymopapain
Number of subjects: 69

Group type: COMPARATOR
Intervention: Operated patients
Number of subjects: 69
Study: 509865

Group type: EXPERIMENTAL
Intervention: Radiological and laboratory investigations
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Radiological investigations
Number of subjects: 67
Study: 30238417

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (HP6)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide (HP15)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both HP6 and HP15
Number of subjects: 54
Study: 29137502

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution applied to umbilical cord stumps
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 200
Study: 25727275

Group type: EXPERIMENTAL
Intervention: Computer-based education module plus a sample genomics consent form (n = 65)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sample genomics consent form only (n = 69)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Computer-based education module
Number of subjects: 134
Study: 24270900

Group type: EXPERIMENTAL
Intervention: parecoxib sodium 40 mg (Group P, n=40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tramadol 2 mg/kg (Group T, n=40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: isotonic saline (Group S, n=40)
Number of subjects: 120
Study: 22129522

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (n=3866)
Number of subjects: 7832

Group type: COMPARATOR
Intervention: Diet alone (n=3966)
Number of subjects: 7832
Study: 19445659

Group type: EXPERIMENTAL
Intervention: Clozapine plus aripiprazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clozapine plus haloperidol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clozapine plus aripiprazole and haloperidol
Number of subjects: 100
Study: 17217436

Group type: EXPERIMENTAL
Intervention: PCV7 (n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: PPV23 (n = 24)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both PCV7 and PPV23
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PPV23
Number of subjects: 47
Study: 15889026

Group type: EXPERIMENTAL
Intervention: Handyscale (digital dynamometer)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standardized strength test in the Constant‐Murley shoulder assessment
Number of subjects: 30
Study: 12572527

Group type: EXPERIMENTAL
Intervention: Fusafungine nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 20
Study: 9459381

Group type: EXPERIMENTAL
Intervention: 3.5 g psyllium three times daily
Number of subjects: 8
Study: 7619678

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day-1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg day-1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2474474

Group type: EXPERIMENTAL
Intervention: Coaxial fiber
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naked fiber
Number of subjects: 40
Study: 6117392

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 5
Study: 31217962

Group type: EXPERIMENTAL
Intervention: MFI-led Community Health Worker program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 27136960

Group type: EXPERIMENTAL
Intervention: Split-dose polyethylene glycol (PEG)
Number of subjects: 105
Study: 26281972

Group type: EXPERIMENTAL
Intervention: GLAR + metformin
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: GLAR + sulfonylurea
Number of subjects: 337

Group type: COMPARATOR
Intervention: 3OAD (metformin or glyburide)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: GLAR (substituted for TZD)
Number of subjects: 337
Study: 24411512

Group type: EXPERIMENTAL
Intervention: Longitudinal curriculum on caring for people with disabilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific disabilities curriculum)
Number of subjects: 0
Study: 22070720

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20190646

Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study: 18612703

Group type: EXPERIMENTAL
Intervention: Postoperative combined modality adjuvant therapy (chemotherapy, chemoradiation, or both); specific dosages and durations not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant therapy; specific type not mentioned.
Number of subjects: 0
Study: 15773068

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard pharmaceutical grade placebo
Number of subjects: 19
Study: 12454574

Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein formula
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonhydrolyzed protein formula
Number of subjects: 10
Study: 10086330

Group type: EXPERIMENTAL
Intervention: Daily doses of 9 or 12 x 10(6) IL‐2 units/m2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Daily doses of 3 or 6 10(6) IL‐2 units/m2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (7 patients)
Number of subjects: 18
Study: 7586463

Group type: EXPERIMENTAL
Intervention: CABG within 48 hours after Q-wave infarction
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: CABG between 3 and 5 days after Q-wave infarction
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: CABG after 5 days after Q-wave infarction
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: CABG for non-Q-wave infarction
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control group (CABG for angina without infarction)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: CABG after Q-wave infarction
Number of subjects: 371
Study: 2265095

Group type: EXPERIMENTAL
Intervention: MeZinc (adhesive zinc oxide tape)
Number of subjects: 44

Group type: COMPARATOR
Intervention: DuoDerm (adhesive occlusive hydrocolloid dressing)
Number of subjects: 44
Study: 7139063

Group type: EXPERIMENTAL
Intervention: Sustained release formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three 25 mg conventional doses given at 4‐h intervals (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single 75 mg dose of conventional capsules (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous dose (control)
Number of subjects: 0
Study: 31952174

Group type: EXPERIMENTAL
Intervention: CrM-HMB (0.04 g/kg/day of CrM plus 3 g/day of HMB)
Number of subjects: 28
Study: 30720346

Group type: EXPERIMENTAL
Intervention: ER/DS mask
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham mask
Number of subjects: 19
Study: 28601622

Group type: EXPERIMENTAL
Intervention: 15-minute rope skipping activity with intervals and rests
Number of subjects: 731

Group type: COMPARATOR
Intervention: Usual practices (Control)
Number of subjects: 731
Study: 25898692

Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Skin prick testing (SPT)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: In vitro IgE measurement (CAP/RAST)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 521
Study: 23670958

Group type: EXPERIMENTAL
Intervention: HE3286 (17α‐ethynylandrost‐5‐ene‐3β,7β,17β‐triol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HE3286
Number of subjects: 0
Study: 21971474

Group type: EXPERIMENTAL
Intervention: Cognitive training exercises for verbal memory improvement over a two-month period
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active control group performing other computer activities
Number of subjects: 12
Study: 20084326

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg patch)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg)
Number of subjects: 50
Study: 17027104

Group type: EXPERIMENTAL
Intervention: NO-releasing aspirin (NORA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no diabetes)
Number of subjects: 40
Study: 15478208

Group type: EXPERIMENTAL
Intervention: Essential oil spray or gargle formulation
Number of subjects: 0
Study: 11682284

Group type: EXPERIMENTAL
Intervention: Chronobiological interventions related to reproductive hormones (specific details not provided)
Number of subjects: 0
Study: 10211010

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg kg‐1 as drops
Number of subjects: 44

Group type: COMPARATOR
Intervention: Midazolam 0.1 mg kg‐1 from an intranasal spray device
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Midazolam (both methods)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (both methods)
Number of subjects: 44
Study: 8165823

Group type: EXPERIMENTAL
Intervention: Fenoterol (F) administered intravenously (i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoterol (F) administered orally (p.o.)
Number of subjects: 0
Study: 2893084

Group type: EXPERIMENTAL
Intervention: Serum CA‐125 measurement
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Vaginal examination
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combination of serum CA‐125 measurement with ultrasound
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combination of vaginal examination with ultrasound
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combination of serum CA‐125 measurement with vaginal examination
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combination of all three tests (serum CA‐125 measurement, vaginal examination, ultrasound)
Number of subjects: 1010
Study: 29501386

Group type: EXPERIMENTAL
Intervention: Negative symptoms
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Level of functioning
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Friendship relations
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (olanzapine, clozapine, quetiapine)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Psychotic symptoms and duration of illness
Number of subjects: 428
Study: 28463833

Group type: EXPERIMENTAL
Intervention: 5 mg/h clazosentan
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 10 mg/h clazosentan
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 25030039

Group type: EXPERIMENTAL
Intervention: Children with ALL
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Quadriceps weakness
Number of subjects: 109
Study: 24280476

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic interventions under DRG conditions
Number of subjects: 4598

Group type: COMPARATOR
Intervention: Control group (no DRG system)
Number of subjects: 4598
Study: 21477171

Group type: COMPARATOR
Intervention: Exclusive caesarean section deliveries
Number of subjects: 3763

Group type: COMPARATOR
Intervention: Combination of caesarean and spontaneous vaginal births
Number of subjects: 3763

Group type: COMPARATOR
Intervention: Exclusive caesarean births
Number of subjects: 3763

Group type: COMPARATOR
Intervention: Mixed caesarean and spontaneous vaginal births
Number of subjects: 3763
Study: 18194525

Group type: EXPERIMENTAL
Intervention: Workplace intervention (stepwise approach to return-to-work plan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 15814479

Group type: EXPERIMENTAL
Intervention: GAI‐Estimate (GAI‐E) algorithms developed from the Development group (n=1,200)
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: GAI‐Estimate (GAI‐E) algorithms
Number of subjects: 2401

Group type: COMPARATOR
Intervention: Validation group (n=1,201)
Number of subjects: 2401
Study: 12433231

Group type: EXPERIMENTAL
Intervention: Modafinil (three 100 mg doses per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 10
Study: 10497376

Group type: EXPERIMENTAL
Intervention: Resistive load detection in asthmatic children
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Psychophysical approaches in pediatric asthma
Number of subjects: 103
Study: 8722435

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxazosin and Enalapril
Number of subjects: 0
Study: 1888693

Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg once daily for 3 weeks
Number of subjects: 12
Study: 6353270

Group type: EXPERIMENTAL
Intervention: Butriptyline
Number of subjects: 77

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 77
Study: 31043095

Group type: EXPERIMENTAL
Intervention: Tocilizumab autoinjector (AI)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Tocilizumab prefilled syringe (PFS)
Number of subjects: 215
Study: 29228848

Group type: EXPERIMENTAL
Intervention: Operative group (closed reduction and fixation with a percutaneous screw)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonoperative group (immobilization with plaster)
Number of subjects: 46
Study: 26666771

Group type: EXPERIMENTAL
Intervention: Information leaflet about Vietnam's government‐run scheme and the benefits of health insurance
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Voucher entitling eligible household members to 25% off their annual premium
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Both information leaflet and voucher
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Subsidy-only intervention
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Combined intervention (information leaflet + voucher)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3000
Study: 24035143

Group type: EXPERIMENTAL
Intervention: A‐CHESS smartphone application
Number of subjects: 152
Study: 22151478

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent recovery housing with reinforcement-based treatment (RH + RBT)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Recovery housing alone (RH)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 243
Study: 20854045

Group type: EXPERIMENTAL
Intervention: Minimal Psychological Intervention (MPI)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 187
Study: 16389162

Group type: EXPERIMENTAL
Intervention: Basal insulin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Basal insulin + Pio (30 mg daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sulfonylurea and Metformin (SU+M)
Number of subjects: 57
Study: 14607169

Group type: EXPERIMENTAL
Intervention: Cortical patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcortical patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 11077389

Group type: EXPERIMENTAL
Intervention: Penicillin (28 capsules, 500 mg each, taken every 6 hours for 7 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control (exact details not specified)
Number of subjects: 40
Study: 8724325

Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with lithium or carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics, particularly clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: High doses of neuroleptics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New atypical neuroleptics
Number of subjects: 0
Study: 1580837

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 304
Study: 3899571

Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31013372

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) for peanut allergy over 2 years
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) for peanut allergy
Number of subjects: 57
Study: 30209017

Group type: EXPERIMENTAL
Intervention: Combination therapy (ambrisentan 10 mg plus tadalafil 40 mg)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Monotherapy (either ambrisentan or tadalafil plus placebo)
Number of subjects: 605
Study: 27387743

Group type: EXPERIMENTAL
Intervention: CTC positivity (detected using MICC)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: CTC negativity (not detected using MICC)
Number of subjects: 1221
Study: 24622668

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 788

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 788